Japan CPI slightly higher than expected in July, underlying inflation steady
Matthew C. Kapusta, CEO and Managing Director of uniQure N.V. (NASDAQ:QURE), recently sold a significant portion of company shares, according to a Form 4 filing with the Securities and Exchange Commission. On February 25, Kapusta sold 26,727 ordinary shares at a weighted average price of $10.70, totaling approximately $285,978. This transaction was followed by another sale on February 27, where he sold 6,717 shares at a weighted average price of $11.32, amounting to about $76,036. The sales come as uniQure’s stock has shown significant volatility, with a remarkable 106% gain over the past six months despite recent weakness.
These transactions were conducted to cover estimated withholding taxes upon the vesting of restricted and performance-based share units, as per the automatic sale instructions in the relevant agreements. Following these sales, Kapusta’s direct ownership stands at 580,795 shares. Additionally, on February 26, he acquired 16,324 shares through the vesting of performance-based restricted share units, which were granted under the company’s 2014 Share Incentive Plan. With the company’s earnings report due on March 3rd and current InvestingPro analysis showing the stock as undervalued, investors should note that 13 additional exclusive ProTips are available to help inform investment decisions.
In other recent news, CSL (OTC:CSLLY) Behring has confirmed the long-term efficacy of its HEMGENIX treatment for hemophilia B, showcasing four-year results from the HOPE-B study. The data indicates that HEMGENIX maintains sustained factor IX activity levels and significantly reduces the annualized bleeding rate by approximately 90% over four years. Meanwhile, uniQure has completed enrollment for the first cohort in a Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, following a favorable safety assessment by an Independent (LON:IOG) Data Monitoring Committee. This development allows uniQure to proceed with dosing the second cohort in early 2025. Additionally, H.C. Wainwright has upgraded its price target for uniQure to $70, maintaining a Buy rating based on positive discussions about the company’s AMT-130 program for Huntington’s disease. uniQure has also announced a public offering of 4,411,764 ordinary shares priced at $17 each, aiming to raise approximately $75 million. This offering is expected to close around January 10, 2025, subject to customary conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.